Objective: Although many children with asthma do not experience persistence into adulthood, recent studies have suggested that poorly controlled asthma in childhood may be associated with significant airflow obstruction in adulthood. However, data regarding disease progression are lacking, and clinicians are not yet able to predict the course of a child's asthma. The goal of this article was to assess the current understanding of childhood asthma treatment and progression and to highlight gaps in information that remain.
concept of managing future risk is gaining momentum, yet only a small number of studies have investigated the long-term effects of asthma treatment from childhood into adulthood. Furthermore, evidencebased guidelines appear to have had little impact on improving outcomes, suggesting that a new approach is warranted. 3 The paradigm of childhood asthma management is shifting toward more personalized therapies and earlier intervention. 4, 5 In this narrative review, we discuss the current understanding of childhood asthma treatment, what is known about the long-term effects of these treatments, and highlight open questions that remain.
| THE NATURAL HISTORY OF PEDIATRIC ASTHMA
Similar to adult asthma, the underlying etiology of pediatric asthma symptoms is chronic airway inflammation. Pediatric patients may present with a number of respiratory symptoms, including wheezing, shortness of breath, cough, and reductions in forced expiratory volume in 1 s (FEV 1 ). 2 Symptom presentation can vary significantly over time.
Furthermore, serial measurements of lung function over time are usually limited to patients with the most severe asthma and seldom evaluated over time in less severe patients. Unfortunately, measurement of lung function and other physiologic tests are not feasible for the younger population aged <6 years. Overall, there is a paucity of data investigating diagnosis and treatment of asthma in very young children (aged ≤5 years). Figure 1 outlines criteria for asthma diagnosis by age group, which are adapted from the GINA report. 2 Furthermore, the British Thoracic Society/Scottish Intercollegiate Guidelines Network asthma guidelines suggest obtaining fractional concentration of exhaled nitric oxide (FeNO), airway responsiveness, and spirometry measurements (depending on the child's age) to assess asthma in children, but do not make recommendations about regular follow-up for these tools. 6 It is noteworthy that although children aged ≤5 years have similar asthma symptoms as older patients with asthma, the presentation is complicated by the recurrent wheezing from frequent respiratory infections that occurs in this age group. In fact, in children aged <3 years, wheezing alone is a poor predictor of asthma development later in life. 7 A number of factors have been linked to asthma development in children, including allergic sensitization to aeroallergens and family history of asthma. 8 The 2007 National Asthma Education and Prevention Program (NAEPP) Guidelines for the Diagnosis and Management of Asthma initiated a stepwise model based on an ongoing assessment of asthma severity and control. 9 An increasing step number corresponds to augmenting levels of intervention, and a decreasing step number corresponds to tapering down levels of intervention. Asthma severity refers to the intensity of the disease process, which is intrinsic to an individual's disease; severity is determined upon initiation of treatment. In contrast, asthma control is the degree to which symptoms impact a patient's life (eg, activity limitations); control must be continually assessed in order to adjust therapy accordingly.
The NAEPP guidelines further focus on two domains of severity and control: impairment and risk. Impairment refers to the extent to which the frequency and intensity of asthma symptoms result in functional limitations for the patient, and risk refers to the likelihood of future asthma exacerbations, decline in lung function/lung growth, or adverse effects from medication. Severity also takes into account the amount of medication necessary to achieve control. Achieving and maintaining control is a major goal of asthma therapy; poorly controlled asthma is associated with increased risk of exacerbations. 10 Reducing impairment (eg, by preventing chronic symptoms) as well as minimizing future risk (eg, by preventing exacerbations) are therefore critical to the long-term management of asthma. 9 The 2018 GINA report, which is updated and revised more frequently, also recommends a stepwise approach for asthma therapy. In one study of the progression into adulthood for individuals with moderate to severe childhood asthma, 15% experienced remission and 22% had intermittent asthma. 12 The remaining subjects had persistent asthma, including 14% with mild, 29% with moderate, and 19% with severe asthma. 12 Objective factors predicting remission included lower childhood total serum immunoglobulin E (IgE), fewer positive allergy skin tests, and milder childhood asthma. 12 Remission during adolescence occurs more commonly in males than in females and may account for the greater incidence of asthma in females starting at this age. 15, 16 In addition, fluctuations in estrogen during women's menstrual cycles have been linked to worsening asthma symptoms (perimenstrual asthma). 17 In one study, female patients with asthma who used an oral contraceptive (which stabilizes hormone levels throughout a cycle) had reduced asthma symptoms, improved pulmonary function, and improved asthma control compared with those not taking an oral contraceptive. 17 The Asthma Predictive Index (API) was developed from the Tucson Children's Respiratory Study to help predict which pediatric patients will experience asthma into adulthood and which patients will not develop asthma based on a combination of major and minor criteria for children with frequent wheezing episodes. 18 For a positive API score, major criteria include any one of the following: the presence of physician-diagnosed parental asthma or child eczema; minor criteria 
| THE EFFECTS OF ASTHMA ON LUNG DEVELOPMENT
Severe asthma in childhood can cause inflammation and airway remodeling, potentially leading to persistent airflow obstruction and marked decline in FEV 1 into adulthood. 24 The Melbourne Asthma Study showed that, for children with severe asthma at 7 years of age, only 14% achieved remission by age 50, suggesting that the changes in lung function associated with severe asthma occur early and may not be reversible. 25 An update to this study showed that 75% of patients with chronic obstructive pulmonary disease (COPD) at age 53 had one of three types of lung function trajectories. 26 Childhood asthma was one factor that was associated with the risk of these three trajectories, and of interest, these were the only trajectories that were then associated with moderate to severe COPD later in life.
A study in 285 younger children (aged 2-3 years) with positive API concluded that, although 2 years of inhaled corticosteroids (ICS) could alleviate asthma symptoms during the treatment period, the natural course of the disease was unchanged. These results suggest that ICS therapy can help to control existing asthma symptoms, but it is not effective at preventing asthma in young children at high risk of persistent asthma in childhood. 27 Overall, the connection between Figure 2 ). 28 The two most significant predictors of abnormal lung function growth and decline were reduced FEV 1 in childhood and male sex. 28 Lung development plateaus at approxi- recommended in a specialist's office. 24 In addition, short-term monitoring of peak expiratory flow can be used to evaluate response to treatment because variation in peak expiratory flow is associated with poor asthma control. 2 Ideally, a patient's asthma control should be | 351 assessed 1-3 months after starting treatment and every 3-12 months thereafter, as well as within 1 week of an exacerbation. 2 As a child gets older, additional measures can be taken to protect lung growth, including age-appropriate counseling on smoking avoidance/cessation, assessment of symptom reversibility with conventional therapy, occupational counseling, and environmental assessment.
A number of questionnaires have been validated for the assessment of asthma control in children. 30 The Asthma Control
Test (ACT) is a five-item questionnaire answered monthly by children aged ≥12 years. 31 The Asthma Control Questionnaire (ACQ) and the ACQ for children (cACQ) are seven-question tests that have been validated in children aged ≥6-16 years (cACQ) and in adults (ACQ).
32,33
The Pediatric Asthma Therapy Assessment Questionnaire for Children and Adolescents (pATAQ) is designed for patients aged 6-17 years. 34 The Childhood ACT (cACT) 35 is used for younger children (aged to assess both the impairment and risk domains of asthma control.
Because asthma can be difficult to diagnose in this young population, the TRACK score can be used to identify children with respiratory control problems (TRACK <80), allowing clinicians and caregivers to monitor these children for symptoms consistent with asthma. For older children, the Composite Asthma Severity Index (CASI) is a recently developed assessment tool that has been validated in children aged 5-17 years. 37 CASI is free to use (available at www.asthmaseverity. org), measures overall asthma burden in terms of both impairment and risk, and correlates well with levels of severity.
4,38

| BIOMARKERS OF ASTHMA PHENOTYPES
The use of biomarkers to identify patients with a particular molecular basis for disease and who are therefore most likely to respond to a corresponding treatment is becoming increasingly available to personalize asthma management. 39 For patients with eosinophilic asthma classified as the phenotype type 2-high, a number of biomarkers for inflammation are readily available to the clinician. An easily quantified biomarker is the amount of eosinophils in the blood.
Elevated blood eosinophil counts (>300 cells/µL) have been strongly correlated to more frequent asthma exacerbations. 40 Another potential biomarker, FeNO, is released from bronchial epithelium in response to type 2 cytokines, 41 and it has been shown to be correlated with increased asthma morbidity when simultaneously elevated with blood eosinophils, rather than either indicator alone. 42 In fact, one study of children aged 6-17 years showed that elevated FeNO and eosinophil counts at baseline were associated with favorable responses to inhaled fluticasone propionate over oral montelukast, 43 indicating that FeNO measurement could potentially be used to predict treatment response to ICS. 43, 44 FeNO measurement is straightforward, provides immediate results, and can be performed in both infants and young children. The American Thoracic Society (ATS) recommends that FeNO >35 ppb be used to indicate eosinophilic inflammation in children. 45 FeNO values between 20 and 35 ppb are also considered elevated in children, but should be evaluated carefully in clinical context. 45 With better understanding of the mechanisms driving asthma, opportunities to integrate precision medicine into asthma management are numerous. Using a phenotype-based approach to therapy, in which a specific patient's observable characteristics are considered in making treatment decisions, has the potential to improve outcomes for both children and adults with asthma by addressing their endotype, the mechanism of a patient's disease. 46 For example, biomarkers could be used to identify which pathway should be targeted in a specific patient The INFANT trial conducted by National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet showed that biomarkers of type 2 inflammation, such as blood eosinophil counts, can be used to identify children who may benefit from daily ICS treatment. 47 Evaluation of a child's atopic status could also help to distinguish between patients at risk for persistent asthma, those who are likely to respond to daily ICS therapy, and those likely to develop severe, uncontrolled asthma. Precision treatment of asthma will be especially important in young children, as early identification and individualized therapy for asthma may prevent disease progression. 48 However, prospective studies with or without various interventions other than long-term ICS have not FIGURE 3 Personalized asthma treatment algorithm for uncontrolled asthma. 87 Personalized courses of therapy for uncontrolled asthma from phenotype to targeted treatment. The phenotypes observed in a patient can point to the asthma endotype, which is confirmed by specific biomarkers. The presence of biomarkers then guides treatment decisions and allows the clinician to choose a therapy that will address the underlying pathophysiology of a patient's asthma. ED, emergency department; ICS, inhaled corticosteroids; LRTI, lower respiratory tract illness; LTRA, leukotriene receptor antagonist; mAPI, modified asthma predictive index. From Beigelman and Bacharier, "Management of preschool recurrent wheezing and asthma: a phenotype-based approach," Current Opinion in Allergy and Clinical Immunology, 17(2) 131-138 (2017). Reprinted with permission from Wolters Kluwer Health, Inc. https://journals.lww.com/co-allergy/Abstract/2017/ 04000/Management_of_preschool_recurrent_wheezing_and.14.aspx been done to assess the specific relationship of uncontrolled asthma to long-term fixed airway obstruction. This is another information gap that should be addressed in future studies.
| ICS THERAPY AND LINEAR GROWTH
ICS therapy is part of the recommended long-term treatment to control asthma, but there is concern that initiating this treatment in prepubertal children may cause reductions in final adult height. 9 A study implementing a primate model of childhood asthma reported that ICS therapy also altered alveolarization in rhesus monkeys. 49 for children who used ICS for >12 months. 52 The authors suggested that this effect may be considered clinically insignificant when compared to the known benefits of ICS therapy in controlling childhood asthma, but noted that clinicians should aim to prescribe the lowest effective dose. 52 In addition, current ICS formulations were designed for adults and could potentially lead to greater growth suppression in young children due to a higher dose per weight. 53 
| BIOLOGIC THERAPIES
Biologic agents that target inhibition of IgE and IL-5 are already approved in adults and adolescents, and more agents are currently under investigation in clinical trials including older children. 30, [54] [55] [56] However, specific data in children younger than 12 years and even adolescents are limited. Furthermore, the long-term effects of these therapies remain to be seen; more investigation is still necessary to determine if biologic therapy can prevent disease progression or even reverse airway damage. 57 One agent targeting IgE, which plays a role in allergen sensitization and airway inflammation, is omalizumab, an anti-IgE monoclonal antibody approved by the US Food and Drug Administration (FDA) for asthma with atopy in patients aged ≥6 years. 58 One study in children aged 6-12 years
showed that omalizumab treatment resulted in a larger median reduction in maintenance ICS dosage (100%) compared with placebo (66.7%, P = 0.001), and also significantly reduced the percentage of patients with severe exacerbations (18.2%) compared with placebo (38.5%, P < 0.001) during the 12-week ICS dose-reduction phase of the study. 59 In a subsequent study for the same age group, omalizumab treatment resulted in a 50% reduction in severe exacerbations over 52 weeks compared with placebo (P = 0.004).
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A study is underway with anti-IgE to determine its long-term effect on disease modification in children (ClinicalTrials.gov Identifier:
IL-5 is a cytokine involved in the growth, differentiation, and migration of eosinophils to the airway. severe asthma and elevated eosinophil counts (≥300 cells/µL). 71 In a larger subsequent study, dupilumab improved lung function in addition to reducing severe exacerbations in adult patients with persistent uncontrolled asthma regardless of eosinophil count. 72 The LIBERTY ASTHMA QUEST study investigated the efficacy of dupilumab in patients aged ≥12 years with uncontrolled asthma for 1 year of treatment. 73 These results were similar to the adult studies; dupilumab significantly reduced asthma exacerbation rates, improved lung function, and improved asthma control compared with placebo. Greater benefits were observed for patients with elevated baseline blood eosinophil counts (≥300 cells/µL) and FeNO (≥25 ppb). Dupilumab is also currently being evaluated in younger children aged 6-<12 years with uncontrolled asthma in the VOYAGE study (ClinicalTrials.gov Identifier: NCT02948959). 79 The results of the BARD study investigating the best medication response in black patients will provide further information on ICS and ICS/long-acting β 2 -agonist (LABA) response in children and adults (ClinicalTrials.gov
Identifier: NCT01967173).
The BADGER study investigated the response to different step-up therapies in patients aged 6-17 years with uncontrolled asthma despite the use of low-dose ICS. 76 Children were randomized to receive ICS, LABA, or leukotriene receptor antagonist (LTRA) as add-on therapy for each of the three 16-week periods of the 48-week study. It showed a differential response to asthma therapy based on their racial or ethnic group. 76 Black patients did not respond as well to an LTRA addition as they did to an ICS or LABA, and non-Hispanic white patients did best with the addition of a LABA. 76 Figure 4 illustrates the response to stepup therapy by race, age, and eczema status from the BADGER study.
Although the reasons for this differential response are not clear, it has been suggested that they may be due to genetic variations or gene-byenvironment interactions affecting responsiveness to treatment. 80 A post hoc analysis of the BADGER data further showed that children without a history of eczema responded better to LABA step-up therapy regardless of race. 81 In the CHASE 3 study, budesonide/formoterol combination therapy (80/4.5 µg two inhalations twice daily) resulted in significant, clinically meaningful improvements in lung function compared with budesonide alone in children aged 6-<12 years with symptomatic asthma despite low-dose ICS therapy, and there was no difference in the safety profile. 82 Although CHASE 3 did not stratify treatment by ethnic group or other status, the results supported the use of combined ICS/LABA therapy in children with asthma that was uncontrolled by low-dose ICS therapy alone.
Poor asthma control is strongly associated with exacerbation risk, 10 and having a history of exacerbations is the strongest predictor for future exacerbations. 77 Although these asthma exacerbations are acute events, the accompanying inflammation may trigger sustained pathologic airway remodeling, which negatively affects lung function. 83 Prevention of exacerbations FIGURE 4 Differential probability of best response to step-up therapy in children with asthma. 76 Further investigation is required to determine how clinicians can diagnose and treat asthma earlier in life to prevent additional lung damage and to predict which patients will respond to which interventions; childhood asthma patient registries may aid future analyses. In addition, newer, more personalized therapies that target the molecular mechanisms of an individual's own asthma are showing promise in adults, but more investigation must be done in pediatric patients. In the near future, novel biomarkers that correspond to a specific disease mechanism could soon guide clinicians to choose more effective therapies for each patient.
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